On 13 May 2024, Novo Holdings A/S announced the acquisition of a 60% majority stake in growing Austrian life sciences tools company Single Use Support. The two co-founders of Single Use Support will each retain a 10% stake, and Danaher Corporation will hold the remaining 20%.
Founded in 2017 in Austria, Single Use Support develops equipment and consumables for bioprocessing, focusing on biological drug substances, cell and gene therapies, and mRNA vaccines.
This news follows the 25 March 2024 announcement by Novo Nordisk of its acquisition of Cardior Pharmaceuticals for (up to) € 1.025B.